+1.52%
Today
Loading 1D prices…
Company profile
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Sector
Industrials
Industry
Laboratory Analytical Instruments
Exchange
Nasdaq
Display currency
USD
Location
NEW HAVEN, CT, United States
Employees
61
Fiscal year end
1231
CIK
1043961
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| RPIDRapid Micro Biosystems Inc. Class A Common Stock | $61.7M | $33.6M | -140.30% | -$1.05 | +1.25% | Buy |
| HBIOHarvard Bioscience Inc. Common Stock | $36.6M | $86.6M | -65.51% | -$1.28 | -1.47% | Hold |
| SEERSeer Inc. Class A Common Stock | $108M | $16.6M | -443.96% | -$1.28 | +1.04% | Buy |
| QTRXQuanterix Corporation Common Stock | $121.1M | $138.9M | -77.18% | -$2.51 | +2.20% | Hold |
| NAUTNautilus Biotechnology Inc. Common Stock | $129.8M | $0.00 | — | -$0.47 | +2.53% | Buy |